151012-31-6

Basic information

• Product Name: 3-(4-BROMOBENZYL)-2-BUTYL-4-CHLORO-1H-IMIDAZOL-5-YLMETHANOL
• Synonyms: 3-(4-BROMOBENZYL)-2-BUTYL-4-CHLORO-1H-IMIDAZOL-5-YLMETHANOL;3-(4-BROMOBENZYL)-2-BUTYL-5- CHLORO-3H-IMIDAZOL-4-Y];1-[(4-Bromophenyl)-methyl]-2-butyl-4-chloro-1H-imidazole-5-methanol;2-Butyl-1-(4-bromobenzyl)-4-chloro-5-(hydroxymethyl)-1H-imidazole;1H-Imidazole-5-methanol,1-[(4-bromophenyl)methyl]-2-butyl-4-chloro-;1-(4-Bromobenzyl)-2-butyl-4-chloro-1H-imidazole-5-methanol;[1-(4-Bromobenzyl)-2-butyl-4-chloroimidazol-5-yl]methanol;(1-(4-bromobenzyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol
• CAS NO: 151012-31-6
• Molecular Formula: C₁₅H₁₈BrClN₂O
• Molecular Weight: 357.68
• Product Categories: Aromatics;Heterocycles;Intermediates
• Mol File: 151012-31-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 491.953 °C at 760 mmHg
• Flash Point: 251.324 °C
• Appearance: /
• Density: 1.42
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• PKA: 13.65±0.10(Predicted)
• CAS DataBase Reference: 3-(4-BROMOBENZYL)-2-BUTYL-4-CHLORO-1H-IMIDAZOL-5-YLMETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-BROMOBENZYL)-2-BUTYL-4-CHLORO-1H-IMIDAZOL-5-YLMETHANOL(151012-31-6)
• EPA Substance Registry System: 3-(4-BROMOBENZYL)-2-BUTYL-4-CHLORO-1H-IMIDAZOL-5-YLMETHANOL(151012-31-6)

Safety Data

• Hazardous Substances Data: 151012-31-6(Hazardous Substances Data)

Usage

Description

3-(4-BROMOBENZYL)-2-BUTYL-4-CHLORO-1H-IMIDAZOL-5-YLMETHANOL is an organic compound characterized by its white to off-white solid appearance. It is a complex molecule with a unique structure that features a benzyl group, a butyl group, and an imidazol ring, among other functional groups. 3-(4-BROMOBENZYL)-2-BUTYL-4-CHLORO-1H-IMIDAZOL-5-YLMETHANOL is known for its potential applications in various industries due to its chemical properties.

Uses

Used in Pharmaceutical Industry:
3-(4-BROMOBENZYL)-2-BUTYL-4-CHLORO-1H-IMIDAZOL-5-YLMETHANOL is used as an intermediate in the preparation of Losartan derivatives. Losartan is a medication used to treat high blood pressure and has also been found to be effective in treating other conditions such as heart failure and diabetic nephropathy. The compound plays a crucial role in the synthesis of these derivatives, contributing to the development of new and improved pharmaceutical products.
Used in Chemical Synthesis:
In addition to its applications in the pharmaceutical industry, 3-(4-BROMOBENZYL)-2-BUTYL-4-CHLORO-1H-IMIDAZOL-5-YLMETHANOL can also be utilized in various chemical synthesis processes. Its unique structure and functional groups make it a valuable building block for creating a wide range of compounds with diverse applications, including but not limited to, agrochemicals, dyes, and other specialty chemicals.
Used in Research and Development:
Due to its complex structure and potential applications, 3-(4-BROMOBENZYL)-2-BUTYL-4-CHLORO-1H-IMIDAZOL-5-YLMETHANOL is also used in research and development settings. Scientists and researchers can leverage this compound to explore new chemical reactions, investigate its properties, and potentially discover novel applications in various fields.

InChI:InChI=1/C15H18BrClN2O/c1-2-3-4-14-18-15(17)13(10-20)19(14)9-11-5-7-12(16)8-6-11/h5-8,20H,2-4,9-10H2,1H3

Upstream product

• 79047-41-9 2-n-butyl-4-chloro-5-hydroxymethylimidazole 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 83857-96-9 2-n-butyl-4-chloro-1H-imidazol-5-carboxaldehyde 
• 143722-29-6 3-(4-bromobenzyl)-2-butyl-5-chloro-3h-imidazole-4-carboxaldehyde 
• 106-38-7 para-bromotoluene 

Downstream Products

• 133909-99-6 2-n-butyl-4-chloro-1-[(2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]-1H-imidazole-5-methanol 
• 114798-26-4 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole 
• 124750-99-8 cozaar 
• 114772-55-3 2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)-methyl]-5-(hydroxymethyl)imidazole 
• 852357-69-8 (2-butyl-5-chloro-3-{2'-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-biphenyl-4-ylmethyl}-3H-imidazol-4-yl)-methanol 

Relevant articles and documents

Continuous Synthesis and Separation ofp-Bromobenzyl Bromide Using Atom-Efficient Bromination ofp-Bromotoluene without Any Organic Effluent: Potential for Green Industrial Practice

This work focuses on the bromination ofp-bromotoluene (PBT) using different brominating agents such as liquid Br2, NaBr-NaBrO3, NaBr-NaBrO3-NaCl, NaBr-H2O2, and HBr-H2O2. NaBr-NaBrO3-NaCl is an eco-friendly brominating agent obtained from a bromine recovery plant. Both NaBr-NaBrO3and NaBr-NaBrO3-NaCl were found to be nonhazardous and efficient brominating agents. Pure NaBr-NaBrO3resulted in the best PBT conversion with 79.7% Br atom efficiency in water and 98.2% average Br atom efficiency using dichloroethane as a solvent. Dichloroethane is de facto no longer used in the US and Europe and is not eco-friendly; the process with water as a solvent is the best. The substrate to active bromine molar ratio of 3:1 was found to be sufficient to get the maximum selectivity ofp-bromobenzyl bromide (PBBB). The low-temperature crystallization method was used for separation cum purification of the product. Unreacted PBT was recycled along with the dibromo byproduct obtained. The dibromo product, which was built up gradually in the reaction mixture over 10 successive batches, was converted back into PBBB/PBT through NaBH4treatment of the mother liquor. This continuous process is highly sustainable and produces zero organic waste, making it potentially attractive toward green industrial implementation.

Process for the preparation of benzylimidazole derivatives and for losartan

A process for the preparation of benzylimidazole derivatives useful as intermediates for preparation of losartan, novel intermediates for their preparation and a process for the preparation of losartan.

Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients

The present invention relates to the use, for the preparation of drugs to increase the survival rate of transplant patients, including renal and heart transplant patients, of a therapeutically effective amount of an angiotension II receptor antagonist compound, such as the class of substituted imidazoles represented by formula (I) and in particular by losartan potassium, 2-butyl-4-chloro-[(2′-tetrazol-5-yl)biphenyl-4-il]methyl]-5-(hydroxymethyl)imidazole potassium salt.